Novel pharmacological approaches in the treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 1, 2005, Pages 1-20

  Schleyer, V ^a   Landthaler, M ^a   Szeimies, Rolf Markus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Biologics; Immunotherapy; Psoriasis; T cells

Indexed keywords

ALEFACEPT; BASILIXIMAB; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; DERMATOLOGICAL AGENT; DITHRANOL; EFALIZUMAB; FUMARIC ACID; HYBRID PROTEIN; IMUCLONE; LEFLUNOMIDE; MERIMEPODIB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 4; PIMECROLIMUS; PLACEBO; RAPAMYCIN; RECEPTOR PROTEIN; RETINOID DERIVATIVE; SIPLIZUMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ANEMIA; APHTHOUS STOMATITIS; BONE MARROW SUPPRESSION; BURNING SENSATION; CAPILLARY LEAK SYNDROME; CELL GROWTH; CELLULAR IMMUNITY; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG DESIGN; DRUG ERUPTION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EPIDERMIS CELL; ERYTHEMA; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEAT SENSATION; HUMAN; HUMORAL IMMUNITY; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNOMODULATION; INJECTION SITE REACTION; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN ATROPHY; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING;

DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; PSORIASIS;

EID: 14044265006     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01070.x     Document Type: Review

References (218)

1. Weinstein GD, Krueger JG. An overview of psoriasis. In: Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis. Portland National Psoriasis Foundation, Portland, Oregon, 1993: 1-22.
2. Christophers E, Kiene P. Guttate and plaque psoriasis. Dermatol Clin 1995; 13: 751-756.
3. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
4. Strange P, Cooper KD, Hansen ER et al. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 1993; 101 695-700.
5. de Rie MA, Bos JD. Immunological aspects ofpsoriasis. Neth J Med 1998; 53: 143-144.
6. Gottlieb AB, Krueger JG. Role of T-lymphocytes (in psoriasis pathogenesis). In: Dubertret L, ed. Psoriasis. ISED, Brescia, 1994: 63-71.
7. Griffiths TW, Griffiths CEM, Voorhees JJ. Immunopathogenesis and immunotherapy of psoriasis. Dermatol Clin 1995; 13: 739-749.
8. Baker BS, Griffiths CEM, Lambert S et al. The effects of cyclosporine A on T lymphocytes and dendritic cell subpopulations in psoriasis. Br J Dermatol 1987; 116: 503-510.
9. Bos JD, Meinardi MM, van Joost T et al. Use of cyclosporine in psoriasis. Lancet 1989; 2: 1500-1502.
10. Mueller W, Hermann B. Cyclosporine A for psoriasis. N Engl J Med 1979; 301: 555.
11. Vallat VP, Gilleaudeau P, Battat L et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-296.
12. Barker BS, Swain AF, Griffiths CEM et al. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis. The effect of PUVA treatment. Clin Exp Immunol 1985; 61: 526-534.
13. Eedy DJ, Burrows D, Bridges JM, Jones FGC. Clearance of severe psoriasis after allogenic bone marrow transplantation. Br J Med 1990; 300: 908.
14. Gardembas-Pain M, Ifrah N, Foussard C et al. Psoriasis after allogeneic bone marrow transplantation. Arch Dermatol 1990; 126: 1523.
15. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-1887.
16. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
17. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990; 94: 135-140.
18. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-884.
19. Barker JN. Genetics of psoriasis. Clin Exp Dermatol 2001; 26: 321-325.
20. Christophers E. Psoriasis: mechanisms and entry points for possible therapeutic interventions. Australas J Dermatol 1996; 37: S4-S6.
21. Martin A, Gutierrez E, Muglia J et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB389IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001; 45: 871-881.
22. Waters CA, Schimke PA, Snider CE et al. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 1990; 20: 785-791.
23. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
24. Gottlieb AB, Bacha P, Parker K, Strand V. Use of interleukin-2 fusion protein DAB389IL-2, for the treatment of psoriasis. Dermatol Ther 1998; 5: 48-63.
25. Bagel J, Garland WT, Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938-944.
26. Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997; 54: 285-294.
27. Sintchak MD, Nimmesgern E. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000; 47: 163-184.
28. Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE. Mycophenolate mofetil: A new immunosuppressive drug in dermatology and its possible uses. Hautarzt 2000; 51: 63-69.
29. Sircar JC, Schwender CF. Antipsoriatic drugs as inhibitors of soybean lipoxygenase, a possible mode of action. Prostaglandins Leukot Med 1983; 11: 373-380.
30. Gomez EC, Menendez L, Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis. J Am Acad Dermatol 1979; 1: 531-537.
31. Jones EL, Epinette WW, Hackney VC et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-542.
32. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis: long term administration. Arch Dermatol 1977; 113: 930-932.
33. Spatz S, Rudnicka A, McDonald CJ. Mycophenolic acid in psoriasis. Br J Dermatol 1978; 98: 429-435.
34. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17: 962-971.
35. Geilen CC, Mrowietz U. Lack of efficacy of topical mycophenolic acid in psoriasis vulgaris. J Am Acad Dermatol 2000; 42: 837-840.
36. Shoji Y, Fukumura T, Kudo M et al. Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced by dinitrofluorobenzene. J Pharm Pharmacol 1994; 46: 643-646.
37. Wohlrab J, Jahn K, Plaetzer M et al. Topical application of mycophenolate mofetil in plaque-type psoriasis. Br J Dermatol 2001; 144: 1262-1295.
38. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-837.
39. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporine to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405-407.
40. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporine therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001; 26: 480-483.
41. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001; 144: 583-586.
42. Geilen CC, Tebbe B, Bartels CG et al. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-1102.
43. Haufs MB, Beissert S, Grabbe S et al. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-181.
44. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999; 40: 135-137.
45. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheum 1993; 11: S117-S119.
46. Sollinger HW. Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 1996; 28: 24-29.
47. Sollinger HW, US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
48. The Tricontinental Mycophenolate Mofetil Renal Transplantation Group. A blinded clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
49. Xu X, Williams JW, Gong H et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996; 52: 527-534.
50. Reich K, Hummel KM, Beckmann I et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002; 146: 335-336.
51. Johnston GA, Rees JL, Reynolds NJ. Leflunomide therapy in severe, unstable psoriasis. Australas J Dermatol 1997; 38: 2062.
52. Wozel G, Pfeiffer C. Leflunomide - A new drug for pharmacological immunomodulation. Hautarzt 2002; 53: 309-315.
53. Bluestone JA, Khattri R, van Seventer GA. Accessory molecules. In: Paul WE, ed. Fundamental Immunology, 4th edn. Lippincott-Raven, Philadelphia, 1998: 3867-3877.
54. Gottlieb AB, Krueger JG, Wittkowski K et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591-600.
55. Granstein RD. New treatments for psoriasis. N Engl J Med 2001; 345:284-287.
56. Papp K, Bissonnette R, Krueger JG et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45: 665-674.
57. Gottlieb A, Krueger JG, Bright R et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42: 428-435.
58. Gottlieb AB, Menter A, Duvic M et al. Efalizumab (anti-CD11a) induction and maintenance: treatment during a 12-month trial in patients with moderate to severe plaque psoriasis: preliminary findings. Presented at: American Academy of Dermatology 60th Annual Meeting, 2002: poster 546.
59. Gottlieb AB, Blacker K, Duvic M et al. Efficacy and safety of efalizumab (anti-CD11a) long-term treatment: preliminary findings from an open-label trial. Presented at: American Academy of Dermatology Meeting, San Francisco, March 21-26, 2003: poster 11.
60. Gordon KB, Papp KA, Hamilton TK et al., Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. J Am Med Assoc 2003; 290: 3073-3080.
61. Lebwohl M, Tyring SK, Hamilton TK et al., Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Eng J Med 2003; 349: 2004-2013.
62. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995; 105: 89S.
63. Gottlieb AB, Lebwohl M, Shirin S et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595-604.
64. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320-321.
65. Rizova H, Nicolas JF, Morel P et al. The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin. J Dermatol Sci 1994; 7: 1-13.
66. Morel P, Revillard JP, Nicolas JF et al. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J Autoimmun 1992; 5: 465-477.
67. Thivolet J, Nicolas JF. Immunointervention in psoriasis with anti-CD4 antibodies. Int J Dermatol 1994; 33: 327-332.
68. Bachelez J, Flageul B, Dubertret L et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 1998; 11: 53-62.
69. Isaacs JD, Burrows N, Wing M et al. Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997; 110: 158-166.
70. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105 105-116.
71. Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Invest Drugs 2000; 9: 2147-2157.
72. Abrams JR, Kelley SL, Hayes E et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-694.
73. Gimmi CD, Freeman GJ, Gribben JG et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88: 6575-6579.
74. Nickoloff B, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today 1994; 15 464-469.
75. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-1252.
76. June CH, Ledbetter JA, Gillespie MM et al. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987; 7: 4472-4481.
77. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
78. Branco L, Barren P, Mao SY et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588-1596.
79. Matheson R, Beutner K, McCall C, Dingivan C. Subcutaneous injection of MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis: phase I results. J Invest Dermatol 2001; 117: S817.
80. Langley R, Roenigk H, McCall C, et al. Phase I results of intravenous MEDI-507, an anti-T-cell monoclonal antibody, for the treatment of psoriasis. J Invest Dermatol 2001; 117: S817.
81. Majeau GR, Meier W, Jimmo B et al. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. J Immunol 1994; 152: 2753-2767.
82. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4: 131-139.
83. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
84. Ortonne JP, Lebwohl M, Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13: 117-123.
85. Krueger GG, Papp KA, Stough DB et al. A randomized double-blind placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-833.
86. Kaempfer R. Regulation of the human interleukin-2/interleukin-2 receptor system: a role for immunosuppression. Proc Soc Exp Biol Med 1994; 206: 176-180.
87. Nashan B, Light S, Hardie IR et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110-115.
88. Krueger JG, Walters JB, Miyazawa M et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-458.
89. Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-1198.
90. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143: 1121-1122.
91. Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol 2000; 136: 675-676.
92. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25: 195-197.
93. Cardenas ME, Muir RS, Breuder T, Heitman J. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J 1995; 14: 2772-2783.
94. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today 1992; 13: 136-141.
95. Paul C, Ho VC. Ascomycins in dermatology. Semin Cutan Med Surg 1998; 17: 256-259.
96. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not affect collagen biosynthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
97. Bornhovd EC, Schuler E, Bieber T, Wollenberg A. Immunosuppressive macrolides and their use in dermatology. Hautarzt 2000; 51: 646-654.
98. Goto T, Kino T, Hatanaka H et al. FK 506: Historical perspectives. Transplant Proc 1991; 23: 2713-2717.
99. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporine A, FK-506 and rapamycin. J Invest Dermatol 1994; 102: 84-88.
100. De Rie MA, Zonneveld IM, Witkamp L et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol 1996; 76: 357-360.
101. Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporine A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. J Dermatol Sci 1996; 12: 246-254.
102. Schulz BS, Michel G, Wagner S et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993; 151: 4399-4406.
103. Lemster BH, Carroll PB, Rilo HR et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995; 99: 148-154.
104. Jegasothy BV, Ackerman CD, Todo S et al. Tacrolimus (FK 506) - a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992; 128: 781-785.
105. Thomson AW, Nalesnik M, Abu-Elmagd K, Starzl TE. Influence of FK 506 on T lymphocytes, Langerhans cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. Transplant Proc 1991; 23: 3330-3331.
106. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind placebo-controlled study. Arch Dermatol 1996; 132: 419-423.
107. Rilo HLR, Subbotin VM, Selby RR, Thomson AW. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK 506) therapy. Transplantation 1995; 59: 1350-1353.
108. Skaehill PA. Tacrolimus in dermatologic disorders. Ann Pharmacother 2001; 35: 582-588.
109. Ruzicka T, Assmann T, Homey B. Tacrolimus. The drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-580.
110. Reitamo S, Rissanen J, Remitz A et al. Tacrolimus ointment does not effect collagen synthesis: result of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
111. Remitz A, Reitamo S, Erkko P et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999; 141: 103-107.
112. Zonnefeld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-1102.
113. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000; 80: 451.
114. Freeman AK, Linowski GJ, Brady C et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003; 48: 564-568.
115. Cather J, Menter A. Novel therapies for psoriasis. Am J Clin Dermatol 2002; 3: 159-173.
116. Beveca D, Schuler W, Schulz M et al. SDZ ASM 981 - a novel anti-inflammatory macrolactam: pharmacological activities in vitro. Aust J Dermatol 1997; 38: 285.
117. Ho V. Treating the pathophysiological mechanisms of atopic dermatitis. Presented at: Satellite Workshop: New Treatment Strategies - Atopic Dermatitis, 2001.
118. Meingassner JG, Fahrngruber H, Bavandi A. SDZ ASM 981, in contrast to CyA and FK506, does not suppress the primary immune response in murine allergic contact dermatitis. J Invest Dermatol 2000; 114: 832.
119. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119: 876-887.
120. Gottlieb AB, Ho V, Dubertret L et al. Efficacy and safety of oral pimecrolimus in patients with moderate to severe chronic plaque-type psoriasis: a randomized dose-finding study. Presented at: American Academy of Dermatology 61st Annual Meeting, Scientific Posters, 2003.
121. Mrowietz U, Graeber M, Bräutigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
122. Mrowietz U, Wustlich S, Hoexter G et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83: 351-353.
123. Stutz A, Grassberger M, Meingassner JG. Development and pre-clinical aspects of pimecrolimus. Hautarzt 2003; 54: 405-412.
124. Yocum DE. Cyclosporine, FK 506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 1996; 22: 133-154.
125. Reitamo S, Spuls P, Sassolas B et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporine in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438-445.
126. Kaplan MJ, Ellis CN, Bata-Csorgo Z et al. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis. Arch Dermatol 1999; 135: 553-557.
127. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46 1-23.
128. 2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-46.
129. Asadullah K, Sterry W, Stephanek K et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-794.
130. De Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann Med 1995; 27: 537-541.
131. De Jong R, Bezemer AD, Zomerdijk TPL et al. Selective stimulation of T helper 2 cytokine responses by the antipsoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067-2074.
132. Kang S, Yi S, Griffiths CE et al. Calcipotriene-induced improvements in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998; 138: 77-83.
133. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992; 149: 3865-3871.
134. Asadullah K, Docke WD, Ebeling M et al. Interleukin-10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999; 135: 187-192.
135. Reich K, Bruck M, Graefe A et al. Treatment of psoriasis with interleukin-10. J Invest Dermatol, 1998; 111: 1235-1236.
136. Reich K, Garbe C, Blaschke V et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 2001; 116: 319-329.
137. Kimball AB, Kawamura T, Tejura K et al. Clinical and immunologic assessment of patients with psoriasis in a randomized double-blind placebo-controlled trial using recombinant human interleukin-10. Arch Dermatol 2002; 138: 1341-1346.
138. Friedrich M, Döcke W-D, Klein A et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest 2002; 118: 672-677.
139. Trepicchio WL, Ozawa M, Walters IB et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-1537.
140. Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151.
141. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 1997; 336: 1066-1072.
142. Baeten D, Kruithof E, Van den Bosch F et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 186-195.
143. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-1081.
144. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother 2001; 2: 75-84.
145. Sands BE, Tremaine WJ, Sandborn WJ et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-90.
146. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.
147. Scallon BJ, Arevalo Moore M, Trinh H et al. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine 1995; 7: 251-259.
148. Van den Bosch F, Kruithof E, Baeten D et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondylarthropathy: an open pilot study. Am Rheum Dis 2000; 59: 428-433.
149. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
150. Ogilvie ALJ, Antoni C, Dechant C et al. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-589.
151. Schopf RE, Aust H, Knop J. Treatment of psoriasis with chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002; 46: 886-891.
152. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-284.
153. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis. Arch Dermatol 2002; 138: 664-648.
154. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13: 16-22.
155. Tan MH, Gordon M, Lebwohl O et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-933.
156. Kruithof E, Van den Bosch F, Baeten D et al. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondylarthropathy: one year follow up. Ann Rheum Dis 2002; 61: 207-212.
157. Kwon HJ, Cote TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Int Med 2003; 138: 807-811.
158. Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E. Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol 2002; 31: 44-45.
159. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68-75.
160. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
161. Leonardi CL, Powers JL, Matheson RT et al., Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
162. Zeltser R, Valle L, Tanck C et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions 0associated with etanercept. Arch Dermatol 2001; 137 893-899.
163. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-2869.
164. Baghai M, Osmon DR, Wolk DM et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001; 76: 653-656.
165. Barone D, Krantz C, Lambert D et al. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion. Arthritis Rheum 1999; 42: S90.
166. Scallon B, Cai A, Shealy D et al. New comparisons of two types of TNF-α antagonists approved for rheumatoid arthritis. Arthritis Rheum 2000; 43: S226.
167. Wetterberg L, Alexius B, Sääf V et al. Peptide T in treatment of AIDS. Lancet 1987; ii: 159.
168. Marcusson JA, Wetterberg L. Peptide T in the treatment of psoriasis and psoriatic arthritis. A case report. Acta Derm Venereol (Stockh) 1989; 69: 86-88.
169. Marcusson JA, Lazega D, Pert C et al. Peptide T and psoriasis. Acta Derm Venereol (Stockh) 1989; 146: S117-S121.
170. Farber E, Cohen E, Trozak D, Wilkinson D. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 1991; 25: 658-664.
171. Marcusson JA, Talme T, Wetterberg L, Johansson O. Peptide T a new treatment for psoriasis? Acta Derm Venereal (Stockh) 1991; 71: 479-483.
172. Delfino M, Fabbrocini G, Brunetti B et al. Peptide T in the treatment of severe psoriasis. Acta Derm Venereol (Stockh) 1992; 72: 68-69.
173. Gulliver WP, Adams M, Farrand D, Farber E. Peptide T - a novel neuro peptide analog for the treatment of psoriasis. Br J Dermatol 1999; 141: 980.
174. Iversen OJ, Dalen AB. The major internal protein, p27, of a retrovirus like particle is expressed in blood lymphocyte from psoriatic patients. Arch Virol 1985; 85: 197-207.
175. Raychaudhuri SK, Raychaudhuri SP, Farber EM. Anti-chemotactic activities of peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis. Int J Immunopharmacol 1998; 20 661-667.
176. Horsburgh CR Jr. Epidemiology of disease caused by nontuberculosis mycobacteria. Semin Respir Infect 1996; 11: 244-251.
177. Stanford JL, Stanford CA. Immunotherapy of tuberculosis with Mycobacterium vaccae NCTC 11659. Immunobiology 1994; 191 555-563.
178. Stanford JL, Bahr GM, Rook GA et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990; 71: 87-93.
179. Prior JG, Khan AA, Cartwright KA et al. Immunotherapy with Mycobacterium vaccae combined with second line chemotherapy in drug-resistant abdominal tuberculosis. J Infect 1995; 31: 59-61.
180. Rambukkana A, Das PK, Witkamp L et al. Antibodies to mycobacterial 65-kDa heat shock protein and other immunodominant antigens in patients with psoriasis. J Invest Dermatol, 1993; 100: 87-92.
181. Ramu G, Prema GD, Balakrishnan S et al. A preliminary report on the immunotherapy of psoriasis. Indian Med Gazette 1990; 124: 381-382.
182. Lehrer A, Bressanelli A, Wachsmann V et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 1998; 21: 71-77.
183. 2 shift. Res Virol 1996; 147: 103-108.
184. Balagon MV, Walsh DS, Tan PL et al. Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae. Int J Dermatol, 2000; 39: 51-58.
185. Balagon MV, Tan PL, Prestidge R et al. Improvement in psoriasis after intradermal administration of delipidated, deglycolipidated Mycobacterium vaccae (PVAC): results of an open-label trial. Clin Exp Dermatol 2001; 26: 233-241.
186. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998; 93: 307-313.
187. Boehm MF, Heyman RA, Nagpal S. A new generation of retinoid drugs for the treatment of dermatological diseases. Emerging Drugs 1997; 2: 287-303.
188. Saurat JH. Retinoids and psoriasis. Novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999; 41: S2-S6.
189. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin
190. Nagpal S, Chandraratna RAS. Retinoids as anti-cancer agents. Curr Pharm Des 1996; 2: 295-316.
191. Nagpal S, Athanikar J, Chandraratna RAS. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 1995; 270: 923-927.
192. DiSepio D, Malhotra M, Chandraratna RAS, Nagpal S. Retinoic acid receptor-nuclear factor-interleukin 6 antagonism. A novel mechanism of retinoid-dependent inhibition of a keratinocyte hyperproliferative differentiation marker. J Biol Chem 1997; 272: 25555-25559.
193. Krueger GG, Drake LA, Elias PM et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998; 134: 57-60.
194. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355-358.
195. Lebwohl M, Ast E, Callen JP et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 194; 38: 705-711.
196. Lebwohl MG, Breneman DL, Goffe BS et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad 1998; 39: 590-596.
197. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001; 40: 64-66.
198. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000; 22: 1225-1238.
199. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001; 40: 210-212.
200. Koo JYM, Lowe NJ, Lew-Kaya DA et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000; 43: 821-828.
201. Smit JV, de Jong EMGJ, van Hooijdonk CAEM et al. Systemic bexarotene (targretin) significantly inhibits proliferation and inflammation and improves differentiation in moderate to severe plaque psoriasis: a clinical and immunohistochemical study. Br J Dermatol 1999; 141: 969-1000.
202. Smit JV, de Jong E, van Hooijdonk CAEM et al. A multicentre phase II clinical and immunohistochemical trial of systemic bexarotene (targretin) in psoriasis. J Invest Dermatol, 2000; 114: 776.
203. Franssen ME, Smit JV, Van Erp PE, Van De Kerkhof PC. A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion. Br J Dermatol 2003; 149 506-512.
204. Moore AY, Low C. Oral bexarotene and UVB phototherapy in the treatment of moderate-to-severe plaque psoriasis. Presented at: American Academy of Dermatology 61st Annual Meeting, 2003; poster 613.
205. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004; 150: 545-553.
206. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-424.
207. Ellis CN, Varani J, Fisher GJ et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferation activated receptor gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136: 609-616.
208. Clark RB, Bishop-Bafley D, Estrada-Hernandez T et al. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol 2000; 164: 1364-1371.
209. Jiang CY, Ting AT, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
210. Pershadsingh HA, Sproul JA, Benjamin E et al. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 1998; 134 1304-1305.
211. Kuenzli S, Saurat JH. Effect of topical PFARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study. Dermatology 2003; 206: 252-256.
212. Bryson H, Wagstaff AJ. Liarozole. Drugs Aging 1996; 9: 478-484.
213. Van Wauwe J, van Nyen G, Coene MC et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261: 773-779.
214. Kuijpers AL, Van Pelt JP, Bergers M et al. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol 1998; 139: 380-389.
215. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995; 133: 426-432.
216. Berth-Jones J, Todd G, Hutchinson PE et al. Treatment of psoriasis with oral liarozole: a dose ranging study. Br J Dermatol 2000; 143: 1170-1176.
217. Bhushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145 546-553.
218. Ben-Bassat H. Biological activity oftyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Invest Drugs 2001; 2: 1539-1545.